Видео ютуба по тегу Ctla-4

CTLA4 and attenuation of T cell response
CTLA4 and attenuation of T cell response
CTLA-4 mediated regulation of autoimmunity by Dr. Lucy Walker
CTLA-4 mediated regulation of autoimmunity by Dr. Lucy Walker
Beyond anti-PD-1 and anti-CTLA-4 in melanoma
Beyond anti-PD-1 and anti-CTLA-4 in melanoma
Cancer Immune Checkpoint Inhibitors
Cancer Immune Checkpoint Inhibitors
MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors
MEDI5752: Novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors
IOU YouTube: How does CTLA-4 prevent T- cell activation?
IOU YouTube: How does CTLA-4 prevent T- cell activation?
CTLA-4: The Unwanted Player in Cancer
CTLA-4: The Unwanted Player in Cancer
PD-1 refractory melanoma: BRAF MEK vs IPI/NIVO
PD-1 refractory melanoma: BRAF MEK vs IPI/NIVO
Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways
Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways
The benefits of CTLA-4 treatment
The benefits of CTLA-4 treatment
CheckMate 227: Combining CTLA-4 and PD-L1 in NSCLC
CheckMate 227: Combining CTLA-4 and PD-L1 in NSCLC
Work on CTLA-4 at UC Berkeley and UCSF
Work on CTLA-4 at UC Berkeley and UCSF
Immunotherapy For NSCLC | Immune Checkpoint Inhibitors | CTLA-4 Inhibitors |
Immunotherapy For NSCLC | Immune Checkpoint Inhibitors | CTLA-4 Inhibitors |
Combining glycolysis inhibition & CTLA-4 checkpoint blockade
Combining glycolysis inhibition & CTLA-4 checkpoint blockade
Dr. Fong Discusses Memory T Cell Responses Following Anti-CTLA-4 Antibody Treatment
Dr. Fong Discusses Memory T Cell Responses Following Anti-CTLA-4 Antibody Treatment
Anti-PD-1 or anti-CTLA-4 in first line therapy?
Anti-PD-1 or anti-CTLA-4 in first line therapy?
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors
Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma
Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma
Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung Cancer
Combining CTLA-4 Agents With PD-1/PD-L1 Agents in Lung Cancer